The IP argument is rubbish. Publishing peer reviewed studies actually strengthens IP as it clearly establishes prior art.
And I could understand this strategy if RCE were going balls-to-the-wall getting P2 -> P3 trials ramped up and recruited.
But as we know they are just spinning up endless phase 1 trials that get abandoned, chasing new indications, collecting fat salaries with nothing to show from anything.
Ann: R327 added to WHO List of Antibacterial Products, page-11
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RCE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
55.0¢ |
Change
-0.010(1.79%) |
Mkt cap ! $127.5M | |||
| Open | High | Low | Value | Volume |
| 56.0¢ | 56.5¢ | 55.0¢ | $124.1K | 222.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 44090 | 55.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 56.0¢ | 1761 | 1 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| RCE (ASX) Chart |